Clinical Trials Browser

Prostatic Neoplasms

Prostatic Neoplasms

Prostate Cancer, Hereditary, 7, Prostatic Neoplasms

Prostatic Neoplasms

Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms

Neoplasm Metastasis, Prostatic Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms

Clinical Trials

Abiraterone Acetate, Prednisone, and Apalutamide With or Without Ipilimumab or Cabazitaxel and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer

PREDICT

Study of Olaparib Maintenance Following Cabazitaxel-Carbo in Men With AVPC

Supraphysiological Androgen to Enhance Treatment Activity in Metastatic Castration-Resistant Prostate Cancer, SPECTRA Study

A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer

Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer

M6620 and Carboplatin With or Without Docetaxel in Treating Patients With Metastatic Castration-Resistant Prostate Cancer

CHAMP

CATCH-177

Prostate Cancer Biomarker Enrichment and Treatment Selection

XmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer

CASCARA: Castration Sensitive Carboplatin, Cabazitaxel and Abiraterone

Prostate Cancer Intensive, Non-Cross Reactive Therapy (PRINT) for Castration Resistant Prostate Cancer (CRPC)

Docetaxel and Carboplatin in Treating Patients With Metastatic, Castration Resistant Prostate Cancer Containing Inactivated Genes in the BRCA 1/2 Pathway

Docetaxel and Carboplatin for Patients With mCRPC and DNA-Repair Deficiencies

Carboplatin, Everolimus, and Prednisone in Treating Patients With Metastatic Prostate Cancer That Progressed After Docetaxel

Paclitaxel and Carboplatin in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy

Carboplatin Plus Docetaxel (Taxotere) in Anaplastic Prostate Cancer

PRO-PLAT

Carboplatin and Paclitaxel in Patients With Metastatic, Castrate-Resistant Prostate Cancer

Calcitriol and Carboplatin in Treating Patients With Stage IV Prostate Cancer That Has Not Responded to Hormone Therapy

Chemotherapy, Hormone Therapy, and Radiation Therapy in Treating Patients With Locally Advanced Prostate Cancer

Carboplatin-Etoposide Combination in Hormone-Resistant Prostate Cancers

Weekly Paclitaxel, Low-Dose Estramustine, and Carboplatin in the Treatment of Hormone Refractory Prostate Carcinoma

A Study of Docetaxel Plus Carboplatin in Patients With Hormone Refractory Prostate Cancer